Dr. Roy H. Larsen has a Ph.D. and postdoctoral experience in radiopharmaceutical chemistry from University of Oslo, Norway and Duke University, USA, respectively. Dr. Larsen has long experience within drug development and business. He was the main founder of Algeta ASA (founded in 1997, acquired by Bayer in 2014), and he served as Managing Director and later Chief Scientific Officer in Algeta ASA from 1997–2006, where he also was a board member from 1997-2003. He is also one of the founders of Nordic Nanovector ASA (2009), and Oncoinvent AS (2010). Roy H. Larsen was chairman of the board in Nordic Nanovector from 2009 to 2014, and a member of the board until 2016. Dr. Larsen works as a consultant and founder through Sciencons AS.
Dr. Thóra J. Jónasdóttir is a DVM, with Ph.D. and postdoctoral research experience within cancer and clinical trials in mouse models and dogs with spontaneous cancers. Dr. Jónasdóttir was the CEO of Oncoinvent AS from the start-up in 2010 to August 2013, along with a part position at the Norwegian University of Life Sciences as head of the canine cancer research group (until 2015) and as a supervisor of Ph.D. students. Since August 2013 she has worked as the Veterinary Officer for Pet Diseases and Animal Welfare at Icelandic Food and Veterinary Authority. Dr. Jónasdóttir is one of the founders of Oncoinvent AS (2010).
Dr. Adrian Senderowicz is a US Board certified medical oncologist, President of Oncology Drug Development, LLC. Adrian is a highly experienced and talented drug development professional with experience in start-ups and late stage oncology biotech. His 30 years of pharma/biotech/regulatory and clinical trial experience spans discovery/translational research to development and approval of small molecule and antibody-based therapeutics. Previous positions include VP Global Regulatory Oncology at Sanofi and Chief Medical Officer positions in private and public companies such as Ignyta, Cerulean and Tokai. More recently he was the CMO of Constellation pharma, acquired last year by Morphosys Inc. In addition, Adrian was a Medical Officer and Acting Team Leader at the US FDA Division of Oncology Products and an investigator at the US National Cancer Institute. Dr. Senderowicz is currently a board member of Step Pharma and Puma Biotechnology Ltd.
Ludvik Sandnes has more than 40 years of experience from international corporate finance, asset management and investment banking from Norfund, The Royal Bank of Scotland, BDO Noraudit, PwC Financial Advisors, Christiania Bank, UNI Storebrand, Orkla Borregaard, Den Norske Creditbank and Statoil. He has experience from more than 20 boards including chairman of Nordic Nanovector. Current board positions also include Oslo Cancer Cluster. He has a Bachelor of Commerce and a degree as Certified European Financial Analyst (AFA) from the Norwegian School of Economics and Business Administration, NHH.
Leiv Askvig has had an international career in the financial industry, having held executive positions and served on the board of numerous companies and organizations, including 19 years in Sundt AS were he was CEO for 17 years, 15 years at Sundal Collier & Co where he was CEO for 5 years, and 5 years as chairman of the board at Oslo Børs VPS Holding ASA. Askvig is currently an Investment Advisor of Sundt AS. He holds board positions with Civita, Eiendomsspar, Ultimovacs AS and Toluma AS. Leiv Askvig has a BBA from BI in Norway and AMP from Harvard Business School.
Ingrid Teigland Akay is a medical doctor and Managing Partner of Hadean Ventures, a European life science fund manager with offices in Oslo and Stockholm. Ingrid has over a decade’s experience working within life science venture capital, supporting companies both in Europe and the US. Prior to establishing Hadean Ventures, Ingrid was working for Inventages, a London-based, global life science VC firm. Before her investment career, Ingrid worked within surgery and internal medicine at hospitals in Norway and the UK. Ingrid holds a medical degree from Medizinische Hochschule Hannover, as well as an MBA in Finance from London Business School.
+47 464 40 045
Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.
With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.